CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Eszopiclone +1 moredrug
Likely dose
Eszopiclone 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724282
NCT00724282Phase 4Completed
CompareCT.gov

Double-blind Placebo-controlled Study of the Effects of Eszopiclone on Glucose Tolerance, Insulin Secretion, and Insulin Action in Adults With Chronic Insomnia

University of Chicago·interventional·Posted Jul 29, 2008·Updated Oct 16, 2015

In Brief

A Phase 4 clinical trial evaluating Eszopiclone and Placebo for Sleep and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Available data suggest that obtaining adequate sleep is associated with a better ability of the body to use carbohydrates as a source of energy and a lower risk of developing diabetes. The sleeping pill, Eszopiclone (Lunesta), has been approved by the Food and Drug Administration for the treatment of people who complain of trouble falling or staying asleep. This study will examine the hypothesis that the use of Eszopiclone (Lunesta) to improve the sleep of people with insomnia may also improve the use of sugar in their body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep, Insomnia, Insulin Resistance
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2008
Enrollment StartApr 1, 2008
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.9 years ago

Interventions

Eszopiclonedrug

Eszopiclone 3 mg by mouth daily at bedtime for 9 days

Placebodrug

Placebo by mouth daily at bedtime for 9 days